let ntp = {
    "inv3": "In the WHO5 classification, MECOM rearrangement is indicative of AML with a defining genetic abnormality, regardless of blast count.  In the ELN Standardized Reporting System for genetic abnormalities in AML, MECOM rearrangement is in the adverse risk prognostic group.",

    "chr5": "Isolated deletion of 5q involving breakpoints in the 5q31q33 region is an MDS-defining cytogenetic abnormality in the current WHO5 classification.  The presence of other cytogenetic abnormalities not detectable by this panel should be assessed by standard cytogenetic analysis, if clinically indicated. In the IPSS-R MDS Cytogenetics Scoring system, isolated 5q deletion is within the good prognosis cytogenetics group. Optimal risk stratification requires correlation with molecular studies as well as standard cytogenetics: MDS patients with both del(5q) and mutated TP53 have decreased response to standard therapies such as lenalidomide and have an increased risk of transformation to AML compared to MDS-del5q without mutated TP53. Therefore, next-generation sequencing studies, if not already performed, should be considered.<br><br> Please correlate with other clinical and laboratory information.",

    "mono5": "Monosomy 5 is a recurring cytogenetic abnormality in myeloid neoplasms, especially myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). In MDS, deletion of 5q occurring either in isolation or with one other cytogenetic abnormality other than monosomy 7 or deletion of 7q is associated with a favorable prognosis. In contrast, monosomy 5 is usually seen as part of a complex karyotype, and in that context is associated with a poor prognosis.  For this reason, cytogenetic analysis to investigate for a complex karyotype are recommended, if not already performed, for complete interpretation of these results.",

    "del5q7q": "Loss of 5q and 7q excludes a diagnosis of MDS with isolated 5q deletion in the WHO classification.  This combination is assigned a poor prognosis according to the Revised International Prognostic Scoring System (IPSS-R) for MDS.  In AML, this combination is an adverse prognostic sign.  ",

    "tr69": "In the current WHO5 classification, this rearrangement is indicative of AML with a defining genetic abnormality, DEK::NUP214 fusion and is in the adverse risk prognostic group according to the European LeukemiaNet (ELN) recommendations for AML risk stratification. It is visible as a t(6;9) translocation by cytogenetic analysis in most cases.",

    "chr7": "In the appropriate clinical setting, del(7q) provides presumptive evidence for a myelodysplastic syndrome. Definitive subclassification of MDS requires correlation with next generation sequencing studies that include TP53. In the IPSS-R MDS Cytogenetics scoring system, isolated del(7q) is in the intermediate prognostic subgroup.  However, the presence of other cytogenetic abnormalities not detectable by this panel should be assessed by standard cytogenetic analysis, if clinically indicated, for complete interpretation of these results. In acute myeloid leukemia (AML), deletion of 7q as a sole cytogenetic abnormality is in the intermediate risk prognostic group according to the European LeukemiaNet (ELN) recommendations for AML risk stratification.",

    "mono7": "In the appropriate clinical setting, monosomy 7 provides presumptive evidence for a myelodysplastic syndrome. Definitive subclassification of MDS requires correlation with next generation sequencing studies that include TP53. In the IPSS-R MDS Cytogenetics scoring system, monosomy 7 alone or with one additional anomaly is in the poor prognostic subgroup.  With more than one additional anomaly, it is in the very poor prognostic subgroup In the IPSS-R MDS Cytogenetic Scoring System.  In acute myeloid leukemia (AML), monosomy 7 is in the adverse risk prognostic group according to the European LeukemiaNet (ELN) recommendations for AML risk stratification.",

    "chr8": "In myelodysplastic syndrome (MDS), trisomy 8 as a sole cytogenetic abnormality is assigned an intermediate prognosis according to the Revised International Prognostic Scoring System (IPSS-R) for MDS. In the setting of persistent cytopenia of undetermined origin, however, trisomy 8 as a sole cytogenetic abnormality in the absence of morphologic criteria is not considered definitive of MDS. In acute myeloid leukemia (AML), trisomy 8 as a sole cytogenetic abnormality is assigned an intermediate prognosis according to the European LeukemiaNet (ELN) recommendations for AML risk stratification. ",

    "chr11": "In acute myeloid leukemia (AML), KMT2A (MLL) rearrangements are assigned a poor prognosis according to the European LeukemiaNet (ELN) recommendations for AML risk stratification, except for the t(9;11)(p21.3;q23.3) involving KMT2A-MLLT3, which is assigned an intermediate prognosis. ",

    "chr11del": "In myelodysplastic syndrome (MDS), deletion of 11q as a sole cytogenetic abnormality is assigned a very good prognosis according to the Revised International Prognostic Scoring System (IPSS-R) for MDS.  However, in acute myeloid leukemia (AML), deletion of 11q as a sole cytogenetic abnormality is assigned an intermediate prognosis according to the European LeukemiaNet (ELN) recommendations for AML risk stratification. ",

    "chr11delPartial": "This signal pattern may be the result of an isolated partial deletion of the KMT2A gene or deletion associated with an unbalanced translocation resulting from retention of the derivative chromosome 11 with the 5’ region of the gene and loss of the reciprocal derivative chromosome with the 3’ region of the gene. The clinical significance of the findings is unclear as deletion of 11q as a sole cytogenetic abnormality is assigned a very good prognosis according to the Revised International Prognostic Scoring System (IPSS-R) for MDS, but KMT2A (MLL) gene rearrangements are generally associated with an unfavorable prognosis in myeloid neoplasms except for the t(9;11) translocation, involving KMT2A::MLLT3, which is assigned an intermediate prognosis in the European LeukemiaNet (ELN) recommendations for AML risk stratification.",

    "chr11gain": "Gain of KMT2A signal without rearrangement may occur through a duplication of the locus or gain of chromosome 11/11q.  Gain of the long arm of chromosome 11, including band q23, is a recurring abnormality in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). While trisomy 11 as a sole cytogenetic abnormality is assigned an intermediate prognosis in MDS and AML according to the Revised International Prognostic Scoring System (IPSS-R) and European LeukemiaNet (ELN), respectively, some studies have shown trisomy 11 to be associated a poor prognosis. ",

    "chr11amp": "KMT2A gene amplification can be present as internal partial tandem duplication (PTD) at the molecular level and/or as homogenously staining region (hsr) and double minutes (dmin) detectable by cytogenetic analysis. It may be seen in myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and mixed-phenotype acute leukemia (MPAL) and is associated with poor prognosis.",

    "chr11rearr":"In acute myeloid leukemia (AML), KMT2A (MLL) rearrangements are assigned a poor prognosis according to the European LeukemiaNet (ELN) recommendations for AML risk stratification, except for the t(9;11)(p21.3;q23.3) involving KMT2A-MLLT3, which is assigned an intermediate prognosis. ",

    "ETV6del": "In the current WHO5 classification, in the absence of morphologic dysplasia or molecular confirmation, deletion of chromosome 12p is not MDS-defining.  In the IPSS-R MDS Cytogenetic Scoring System, deletion of chromosome 12p as a sole anomaly is in the good prognostic subgroup.  The presence of other cytogenetic abnormalities not detectable by this panel should be assessed by standard cytogenetic analysis, if clinically indicated, for complete interpretation of these results.",

    "ETV6rearr": "ETV6 rearrangements are rarely observed in myeloid neoplasms. When detected they are associated with the presence of other genetic abnormalities including, sometimes, ETV6::ABL1 fusion, one of the genetic abnormalities defining myeloid/lymphoid neoplasms with eosinophilia in the current WHO5 classification.  If clinically indicated, targeted interphase FISH with the BCR/ASS1/ABL1 probe set should be considered.   Please also correlate with any available cytogenetic analysis for complete interpretation.  ",

    "inv16": "In the WHO5 classification, CBFB rearrangement is indicative of AML with a defining genetic abnormality, CBFB::MYH11 fusion, and is in the favorable risk prognostic group in the European LeukemiaNet (ELN) recommendations for AML risk stratification.  The presence of KIT mutations, which are associated with early relapse and high risk in this AML, does not alter the risk categorization.",

    "del16q": "In acute myeloid leukemia (AML), deletion of 16q as a sole cytogenetic abnormality is assigned an intermediate prognosis according to the European LeukemiaNet (ELN) recommendations for AML risk stratification.  However, it is usually seen as part of a more complex karyotype and adverse risk prognostic grouping.  Correlation with any available cytogenetic study is required for complete interpretation.",

    "TP53": "The loss of chromosome 17/17p raises the possibility of biallelic inactivation of TP53, an MDS-defining abnormality in the current WHO5 classification.  Deletion of chromosome 17p is in the adverse risk prognostic group according to the European LeukemiaNet (ELN) recommendations for AML risk stratification.  Please correlate with molecular studies for TP53 mutation.   ",

    "mono17": "Deletion of chromosome 17p, achieved through monosomy 17 in this case, is in the adverse risk prognostic group according to the European LeukemiaNet (ELN) recommendations for AML risk stratification.  Its detection raises the possibility of biallelic inactivation of TP53, an MDS-defining abnormality in the current WHO5 classification in the appropriate clinical setting.  Please correlate with molecular studies for TP53 mutation.   ",

    "iso17q": "In the current International Consensus Conference classification, MDS/MPN with isolated isochromosome 17q has been added as a new provisional entity.  The disease in these patients pursues an aggressive clinical course with a short median survival owing to high risk of progression to AML.  Isochromosome 17q can also be part of a more complex karyotype.  In MDS, the loss of 17p from this abnormality raises the possibility of bialleic inactivation of TP53, an MDS-defining abnormality in the current WHO5 classification.  Please correlate with molecular analysis for TP53 mutation for complete interpretation, as well as any available cytogenetic analysis.",

    "tri19": "In myelodysplastic syndrome (MDS), trisomy 19 as a sole cytogenetic abnormality is assigned an intermediate prognosis according to the Revised International Prognostic Scoring System (IPSS-R) for MDS. ",

    "tet19": "Trisomy/tetrasomy 19 is strongly associated with myeloid disorders and is an in the IPSS-R Cytogenetic Scoring system is an intermediate-risk prognostic sign. ",

    "chr20": "The current WHO5 classification of MDS does not consider 20q-minus anomaly, when present as the sole anomaly, to be definitive evidence of myelodysplasia in the absence of morphologic criteria or molecular confirmation. In the IPSS-R MDS Cytogenetic Scoring System, isolated deletion of chromosome 20q is in the good prognostic subgroup. The presence of other cytogenetic abnormalities not detectable by this panel should be assessed by standard cytogenetic analysis, if clinically indicated, for complete interpretation of these results.",

    "complex": "The presence of a complex karyotype (3 or more abnormalities) is associated with a poor/very poor prognostic subgroups in MDS and adverse-risk prognostic group in AML.  ",

    "complexGT3": "In myelodysplastic syndrome (MDS), a complex karyotype with >3 cytogenetic abnormalities is in the very poor prognostic subgroup according to the Revised International Prognostic Scoring System (IPSS-R) for MDS.",

    "congruent": "These results are congruent with the most recent cytogenetic analysis on file (CYG25-",

    "correlate": "Please correlate with other clinical and laboratory information, including the pending cytogenetic analysis (CYG25-",

    "whomds": "In the current WHO guidelines, the demonstration of MDS-defining anomalies in a cytopenic patient in the absence of morphologic dysplasia must be by conventional karyotyping to be diagnostic. ",

    "RUNX1": "In the WHO5 classification, RUNX1::RUN1T1 fusion is indicative of AML with a defining genetic abnormality and is in the favorable risk prognostic group according to the European LeukemiaNet (ELN) recommendations for AML risk stratification. The presence of KIT mutations, which are associated with early relapse and high risk in this AML, does not alter the risk categorization. ",

    "RUNX1T1gain": "Gain of signal with the RUNX1T1 probe  may be indicative of trisomy 8, which is assigned an intermediate prognosis according to the European LeukemiaNet (ELN) recommendations for AML risk stratification.",

    "RUNX1gain": "Gain of RUNX1 signal is suggestive of RUNX1 rearrangement with a gene other than RUNX1T1, or trisomy 21. RUNX1 rearrangement to partner genes other than RUNX1T1 as well as trisomy 21 are both assigned an intermediate prognosis according to the European LeukemiaNet (ELN) recommendations for AML risk stratification.",

    "RARA": "PML::RARA fusion is the diagnostic hallmark of acute promyelocytic leukemia (APL) and is associated with response to all-trans retinoic acid (ATRA) andr arsenic trioxide (ATO).",

    "RARA3G":  "The 2R3G signal pattern with the PML/RARA probe set is suggestive of gain of chromosome 17/17q, or a RARA rearrangement with a gene other than PML. If clinically indicated, targeted interphase FISH with the RARA break apart probe should be performed to identify RARA rearrangement not involving PML. Approximately 5% of patients will have a variant translocation involving RARA, and some variant translocations are not associated with good response to standard all-trans retinoic acid/arsenic trioxide therapy.  Please also correlate with any available cytogenetic analysis.",

    "RARAbreak": "RARA gene rearrangement is identified with the RARA breakapart probe. The clinical significance of the rearrangement is dependent on the partner gene involved in the rearrangement. This assay is not designed to detect the fusion partner.  Cytogenetic studies may aid in further characterization of the RARA abnormality.",

    "allothers": "All other probe signals were within normal reference ranges. These findings represent an ABNORMAL result.",

    "multipleGains": "Multiple chromosome gains are usually associated with complex karyotypes, which are adverse-risk in AML, although simple gains are not adverse-risk in the European LeukemiaNet (ELN) recommendations for AML risk stratification.  For complete interpretation, please correlate with other clinical and laboratory information including the pending cytogenetic analysis (CYG25- .",

    "noTargeted": "No targeted rearrangements are identified.",

}
//line breaks have to be given by '<br/>' and without any carriage returns; else error; JSON.parse(JSON.stringify) not required
let references = {
    "inv3": ["Swerdlow", "Dohner", "Greenberg"],
    /* Khoury JD et al.  The 5th edition of the World Health Organization Classification of Haematolymphoid Tumors:  Myeloid and Histiocytic/Dendritic Neoplasms.  Leukemia 2022. doi.org/10.1038/s41375-022-01613-1.<br/>Greenberg PL, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-65.", */

    "mono5": ["Swerdlow", "Greenberg"],     /* "Khoury JD et al.  The 5th edition of the World Health Organization Classification of Haematolymphoid Tumors:  Myeloid and Histiocytic/Dendritic Neoplasms.  Leukemia 2022. doi.org/10.1038/s41375-022-01613-1", */

    "chr5": ["Greenberg", "Schanz", "Swerdlow", "Jadersten"],     /* Greenberg PL, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-65.<br/> Schanz J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30(8):820-9. <br/> Khoury JD et al.  The 5th edition of the World Health Organization Classification of Haematolymphoid Tumors:  Myeloid and Histiocytic/Dendritic Neoplasms.  Leukemia 2022. doi.org/10.1038/s41375-022-01613-1.<br/> Jadersten M, et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol. 2011;29(15):1971-9. ", */

    "del5q7q": ["Swerdlow", "Schanz", "Greenberg"],

    "tr69": ["Swerdlow", "Dohner"],

    "mono7": ["Swerdlow", "Greenberg"],     /* Khoury JD et al.  The 5th edition of the World Health Organization Classification of Haematolymphoid Tumors:  Myeloid and Histiocytic/Dendritic Neoplasms.  Leukemia 2022. doi.org/10.1038/s41375-022-01613-1. ", */

    "chr7": ["Greenberg", "Schanz"],    /*  Greenberg PL, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-65.<br/> Schanz J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30(8):820-9. ",
 */
    "chr8": ["Greenberg", "Schanz", "Swerdlow"],  /* Greenberg PL, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-65.<br/> Schanz J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30(8):820-9.<br/> SKhoury JD et al.  The 5th edition of the World Health Organization Classification of Haematolymphoid Tumors:  Myeloid and Histiocytic/Dendritic Neoplasms.  Leukemia 2022. doi.org/10.1038/s41375-022-01613-1.",
 */
    "chr20": ["Greenberg", "Schanz", "Swerdlow"],  /* Greenberg PL, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-65.<br/> Schanz J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30(8):820-9.<br/> SKhoury JD et al.  The 5th edition of the World Health Organization Classification of Haematolymphoid Tumors:  Myeloid and Histiocytic/Dendritic Neoplasms.  Leukemia 2022. doi.org/10.1038/s41375-022-01613-1.", */


    "chr11": ["Swerdlow", "Dohner"],    /*  Khoury JD et al.  The 5th edition of the World Health Organization Classification of Haematolymphoid Tumors:  Myeloid and Histiocytic/Dendritic Neoplasms.  Leukemia 2022. doi.org/10.1038/s41375-022-01613-1.<br/> Dohner H, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-447", */

    "chr11del": ["Greenberg", "Schanz","Swerdlow", "Dohner"],     /* Greenberg PL, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-65.<br/> Schanz J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30(8):820-9. ", */

    "chr11delPartial": ["Greenberg", "Schanz", "Dohner", "Swerdlow"],     /* Greenberg PL, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-65.<br/> Schanz J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30(8):820-9.<br/> Dohner H, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-447. ", */

    "chr11gain": ["Greenberg", "Dohner", "Wang", "Alseraye"],     /* Greenberg PL, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;20;120(12):2454-65.<br/> Dohner H, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-447.<br/> Wang SA, et al. Trisomy 11 in myelodysplastic syndromes defines a unique group of disease with aggressive clinicopathologic features. Leukemia. 2010;24(4):740-7. <br/> Alseraye FM, et al. Trisomy 11 as an isolated abnormality in acute myeloid leukemia is associated with unfavorable prognosis but not with an NPM1 or KIT mutation. Int J Clin Exp Pathol. 2011;4(4):371-7.", */

    "chr11amp": ["Sak"],

    "chr11rearr": ["Swerdlow", "Dohner"],

    "ETV6del": ["Greenberg", "Schanz", "Swerdlow", "Dohner"],     /* Greenberg PL, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-65.<br/> Schanz J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30(8):820-9. ",
 */
    "ETV6rearr": ["Dohner", "Haferlach"],     /* Dohner H, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-447. <br/> Haferlach C, et al. ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events. Genes Chromosomes Cancer. 2012;51(4):328-37.", */

    "inv16": ["Swerdlow", "Dohner"],

    "del16q": ["Swerdlow", "Dohner"],

    "mono17": ["Greenberg", "Schanz"],    /*  Greenberg PL, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-65.<br/>  Schanz J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30(8):820-9. ", */

    "TP53": ["Greenberg", "Schanz", "Swerdlow", "Dohner"],     /* Greenberg PL, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-65.<br/> Schanz J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30(8):820-9. ", */

    "iso17q": ["Greenberg", "Schanz"],     /* Greenberg PL, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-65.<br/> Schanz J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30(8):820-9.", */

    "tri19": ["Greenberg", "Schanz"],     /* Greenberg PL, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-65.<br/> Schanz J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30(8):820-9." */

    "RARA": ["Swerdlow", "Dohner"],

    "RARAbreak": ["Swerdlow"],

    "RUNX1": ["Swerdlow", "Dohner"],

    "RUNX1gain": ["Swerdlow", "Dohner"],

    "RUNX1T1gain": ["Swerdlow", "Dohner"],

    "multipleGains": ["Chilton"],
    "RARA3G": "",
    "noTargeted":"",
    "complex": ["Schanz", "Greenberg", "Dohner"],
}
let reference_list = {
    "Swerdlow": "Khoury JD et al.  The 5th edition of the World Health Organization Classification of Haematolymphoid Tumors:  Myeloid and Histiocytic/Dendritic Neoplasms.  Leukemia 2022. doi.org/10.1038/s41375-022-01613-1<br>",

    "Dohner": "Dohner H, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-447.<br>",

    "Greenberg": "Greenberg PL, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-65.<br>",

    "Schanz": "Schanz J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30(8):820-9.<br>",

    "Jadersten": "Jadersten M, et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol. 2011;29(15):1971-9.<br> ",

    "Dohner": "Dohner H, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-447.<br>",

    "Wang": "Wang SA, et al. Trisomy 11 in myelodysplastic syndromes defines a unique group of disease with aggressive clinicopathologic features. Leukemia. 2010;24(4):740-7.<br>",

    "Alseraye": "Alseraye FM, et al. Trisomy 11 as an isolated abnormality in acute myeloid leukemia is associated with unfavorable prognosis but not with an NPM1 or KIT mutation. Int J Clin Exp Pathol. 2011;4(4):371-7.<br>",

    "Haferlach": "Haferlach C, et al. ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events. Genes Chromosomes Cancer. 2012;51(4):328-37.<br>",

    "Sak": "Sakhdari A et al.  Homogeneously staining region (hsr) on chromosome 11 is highly specific for KMT2A amplification in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).  Ca Genet. 2019;238:18-22.<br>",

    "Chilton":"Chilton L et al.  Hyperdiploidy with 49-65 chromosomes represents a heterogeneous cytogenetic subgroup of acute myeloid leukemia with differential outcome.  Leukemia 2014;28:321-328.<br>",
   
}


let reference_array = [];//to hold all reference keys
let ref_unique_array = [];//only unique reference keys

function detectedAbnormality(ntpKey,reference){
$('<span>' + ntpKey + '<br>' + '<br>' +'</span>').appendTo('#allntp');
//write the same reference only once
for (let el of reference){reference_array.push(el);}
ref_unique_array = [...new Set(reference_array)];
let final_list=[];//to hold all unique reference values; local variable required else list will grow with each write
for (let el of ref_unique_array){final_list.push(reference_list[el])}
final_list_string = final_list.toString().replace(/<br>,/g , "<br>");  //regex to stop printing of comma before references
document.querySelector("#references").innerHTML=final_list_string;
}

function atypicalPattern(ntpKey){
    $('<span>' + ntpKey + '&nbsp' +'</span>').appendTo('#test');
    $('<span>' + "ATYPICAL INTERPRETATION HERE" + '<br>' + '<br>' + '</span>').appendTo('#allntp');
}
function copyToClipboard() {
  var copyText =
    document.getElementById("reportText").innerText +
    document.getElementById("allReferences").innerText
  navigator.clipboard.writeText(copyText);
  console.log(copyText);
}

function copyInterpToClipboard(){
    var copyText = document.querySelector("#allntp").innerText;
    navigator.clipboard.writeText(copyText);
}

function copyRefsToClipboard(){
    var copyText = document.querySelector("#references").innerText;
    navigator.clipboard.writeText(copyText);
}

function viewItem(div) {
    var x = document.getElementById(div);
    if (x.style.display === "none") {
      x.style.display = "block";
    } else {
      x.style.display = "none";
    }
}
